<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0311222866
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRANZA 5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        107.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pranza contains the active substance olanzapine. Pranza belongs to a group of medicines called antipsychotics and is used to treat the following conditions:&nbsp;</p><ul><li>Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense. &nbsp;</li><li>Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria.</li></ul><p>Olanzapine has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pranza</strong></p><ul><li>If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor. &nbsp;</li><li>If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye)<strong>.</strong></li></ul><p><strong>Warnings and precautions </strong><br />Talk to your doctor or pharmacist before you take Pranza.</p><ul><li>The use of Pranza in elderly patients with dementia is not recommended as it may have serious side effects. &nbsp;</li><li>Medicines of this type may cause unusual movements mainly of the face or tongue. If this happens after you have been given Pranza tell your doctor. &nbsp;</li><li>Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your doctor at once. &nbsp;</li><li>Weight gain has been seen in patients taking olanzapine. You and your doctor should check your weight regularly. Consider referral to a dietician or help with a diet plan if necessary. &nbsp;</li><li>High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking olanzapine. Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Pranza and regularly during treatment. &nbsp;</li><li>Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.</li></ul><p>If you suffer from any of the following illnesses tell your doctor as soon as possible:</p><ul><li>Stroke or &ldquo;mini&rdquo; stroke (temporary symptoms of stroke) &nbsp;</li><li>Parkinson&rsquo;s disease &nbsp;</li><li>Prostate problems &nbsp;</li><li>A blocked intestine (Paralytic ileus) &nbsp;</li><li>Liver or kidney disease &nbsp;</li><li>Blood disorders &nbsp;</li><li>Heart disease &nbsp;</li><li>Diabetes &nbsp;</li><li>Seizures &nbsp;</li><li>If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets).</li></ul><p>If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or &ldquo;mini&rdquo; stroke.</p><p>As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.</p><p><strong>Children and adolescents</strong><br />Pranza is not for patients who are under 18 years.</p><p><strong>Other medicines and Pranza</strong><br />Only take other medicines while you are on Pranza if your doctor tells you that you can. You might feel drowsy if Pranza is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers). &nbsp;</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. &nbsp;</p><p>In particular, tell your doctor if you are taking:</p><ul><li>Medicines for Parkinson&rsquo;s disease. &nbsp;</li><li>Carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Pranza dose.</li></ul><p><strong>Pranza with alcohol</strong><br />Do not drink any alcohol if you have been given Pranza as together with alcohol it may make you feel drowsy.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not be given this medicine when breast-feeding, as small amounts of olanzapine can pass into breast milk. &nbsp;</p><p>The following symptoms may occur in newborn babies, of mothers that have used olanzapine in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p><strong>Driving and using machines</strong><br />There is a risk of feeling drowsy when you are given olanzapine. If this happens do not drive or operate any tools or machines. Tell your doctor.</p><p><strong>Pranza<strong> </strong>contains lactose</strong><br />Pranza contains lactose. Each film-coated tablet of Pranza 5 mg and 10 mg Film-coated Tablets contains 89 mg or 178 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how many Pranza tablets to take and how long you should continue to take them. The daily dose of Pranza is between 5 mg and 20 mg. Consult your doctor if your symptoms return but do not stop taking Pranza unless your doctor tells you to.</p><p>You should take your Pranza tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food. Pranza tablets are for oral use. You should swallow the Pranza tablets whole with water.</p><p>The score line is not intended for breaking the tablet.</p><p><strong>If you take more Pranza than you should</strong><br />Patients who have taken more olanzapine than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away if you experience any of the above symptoms. Show the doctor your pack of tablets.</p><p><strong>If you forget to take Pranza</strong><br />Take your tablets as soon as you remember. Do not take two doses in one day.</p><p><strong>If you stop taking Pranza</strong><br />Do not stop taking your tablets just because you feel better. It is important that you carry on taking Pranza for as long as your doctor tells you.</p><p>If you suddenly stop taking Pranza, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you reduce the dose gradually before stopping treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor immediately if you have:</strong></p><ul><li>Unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;</li><li>Blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately;</li><li>A combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).</li></ul><p>Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood. In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.</p><p>Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.</p><p>Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; drooling; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.</p><p>Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.</p><p>Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen on blood tests and an increase in a type of white blood cells (eosinophilia).</p><p>While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients.</p><p>In patients with Parkinson&#39;s disease olanzapine may worsen the symptoms.</p><p>Unknown side effects include sleepwalking (which involves getting up and walking around while in a state of sleep).</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is olanzapine.</p><p>Each film-coated tablet of Pranza 5 mg Film-coated Tablets contains 5 mg olanzapine.</p><p>Each film-coated tablet of Pranza 10 mg Film-coated Tablets contains 10 mg olanzapine.</p><p>The other ingredients are: <em>Tablet core:</em> Lactose, microcrystalline cellulose, hydroxypropyl cellulose, crospovidone and magnesium stearate. <em>Tablet coat:</em> Opadry white.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pranza 5 mg Film-coated Tablets are white round film-coated tablets embossed with “JI” on one side and “68” on the other side with a break line in aluminum/aluminum blisters.

Pranza 10 mg Film-coated tablets are white round film-coated tablets embossed with “JI” on one side and “69” on the other side with a break line in aluminum/aluminum blisters.

Pack size: 30 Film-coated Tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer</strong><br />Jazera Pharmaceutical Industries<br />AL-Kharrj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي برانزا على المادة الفعالة أولانزابين. برانزا ينتمي إلى مجموعة من الأدوية تسمى مضادات الذهان ويستخدم لعلاج الحالات التالية:</p><ul dir="rtl"><li>الفصام، هو مرض من أعراضه سمع، رؤية أو الإحساس بأشياء ليست موجودة، معتقدات خاطئة، ارتياب شكوك غير اعتيادية، والانسحاب. الأشخاص الذين يعانون من هذا المرض قد يشعرون أيضا بالاكتئاب، القلق أو التوتر.</li><li>نوبات الهوس المتوسطة إلى الشديدة، وهي حالة مع أعراض النشوة أو الإثارة.</li></ul><p dir="RTL">وقد ثبت أن أولانزابين يمنع تكرار هذه الأعراض في المرضى الذين يعانون من الاضطراب ثنائي القطب والذين أبدوا استجابة للعلاج بالأولانزابين في نوبة الهوس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول برانزا</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية (حساسمية مفرطة) للأولانزابين أو أي من المكونات الأخرى من هذا الدواء (المذكورة في القسم 6). يمكن التعرف على رد فعل تحسسي مثل طفح الجلدي، حكة، تورم الوجه، تورم الشفتين أو ضيق في التنفس. إذا حدثت لك اي من هذه الأعراض، أخبر طبيبك.</li><li>إذا كنت قد شخصت سابقاً بمشاكل في العين مثل أنواع معينة من الجلوكوما (زيادة الضغط في العين).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث إلى طبيبك أو الصيدلي قبل تناول برانزا.</p><ul dir="rtl"><li>لا ينصح استخدام برانزا في المرضى المسنين المصابين بالخرف لأنها قد يكون لها آثار جانبية خطيرة.</li><li>الأدوية من هذا النوع قد تسبب حركات غير عادية خاصة في الوجه أو اللسان. إذا حدث هذا بعد إعطائك برانزا أخبر طبيبك.</li><li>في حالات نادرة جداً، الأدوية من هذا النوع قد تسبب مزيج من الحمى، سرعة في التنفس، تعرق، تصلب العضلات وخمول أو نعاس. إذا حدث هذا، اتصل بطبيبك على الفور.</li><li>وقد شوهد زيادة في الوزن في المرضى الذين يتناولون برانزا . يجب عليك أنت وطبيبك فحص وزنك بانتظام. ضع في اعتبارك الإحالة إلى اختصاصي التغذية أو المساعدة في خطة النظام الغذائي إذا لزم الأمر.</li><li>ارتفاع السكر في الدم ومستويات عالية من الدهون (الدهون الثلاثية والكولسترول) قد شوهدت في المرضى الذين يتناولون أولانزابين. ولذلك يجب أن يجري طبيبك فحوصات الدم للتأكد من نسبة السكر ومستويات دهون معينة قبل البدء بتناول برانزا وبانتظام خلال فترة العلاج.</li><li>أخبر الطبيب إذا كنت أنت أو شخص آخر في عائلتك لديكم تاريخ من جلطات الدم، لأن مثل هذه الأدوية ارتبطت بتشكيل جلطات الدم.</li></ul><p dir="RTL">إذا كنت تعاني من أي من الأمراض التالية أخبر طبيبك في أقرب وقت ممكن:</p><ul dir="rtl"><li>السكتة الدماغية أو السكتة الدماغية البسيطة (أعراض مؤقتة من السكتة الدماغية)</li><li>مرض&nbsp;باركنسون</li><li>مشاكل البروستات</li><li>انسداد في الأمعاء (الشلل اللفائفي)</li><li>أمراض الكبد أو الكلى</li><li>اضطرابات الدم</li><li>مرض القلب</li><li>سكري</li><li>نوبات الصرع</li><li>إذا كنت تعلم أنك قد تكون تعاني من نفاد الملح نتيجة الإسهال الشديد لفترات طويلة والقيء أو استخدام مدرات البول (أقراص الماء).</li></ul><p dir="RTL">إذا كنت تعاني من الخرف، يجب عليك أو على مقدم الرعاية الخاص بك/قريبك اخبار طبيبك إذا كنت تعرضت لسكتة دماغية حتى ولو بسيطة في أي وقت مضى.</p><p dir="RTL">كإجراء وقائي روتيني، إذا كنت أكثر من 65 عاماً يجب أن يراقب ضغط الدم من قبل الطبيب.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />برانزا ليس للمرضى الذين هم دون سن 18 عاما.</p><p dir="RTL"><strong>الأدوية الأخرى وبرانزا</strong><br />استخدام الأدوية الأخرى أثناء استخدام برانزا فقط إذا أخبرك طبيبك أنك تستطيع ذلك. من الممكن أن تشعر بالنعاس إذا تناولت برانزا مع مضادات الاكتئاب أو الأدوية التي تؤخذ لعلاج القلق أو للمساعدة على النوم (المهدئات).</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ على وجه الخصوص:</p><ul dir="rtl"><li>الأدوية لمرض باركنسون.</li><li>كَرْبامازِيبين (المضاد للصرع و مثبت المزاج)، فلوڤوكسامين (مضاد للاكتئاب) أو سيبروفلوكساسين (مضاد حيوي) - قد يكون من الضروري لتغيير جرعة برانزا .</li></ul><p dir="RTL"><strong>برانزا مع الكحول</strong><br />لا تشرب أي كحول إذا كنت قد تناولت برانزا مع الكحول فقد يجعلك تشعر بالنعاس.</p><p dir="RTL"><strong>الحمل والرضاعة&nbsp;</strong><br />اطلبي النصيحة من طبيبك قبل تناول هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لإنجاب طفل. يجب عدم إعطائك هذا الدواء أثناء الإرضاع، لأن كميات قليلة من الأولانزابين يمكن أن تمر إلى حليب الثدي.</p><p>قد تحدث الأعراض التالية في الأطفال حديثي الولادة، لدى الأمهات اللواتي تناولن أولانزابين في الثلث الأخير (الأشهر الثلاثة الأخيرة من الحمل): ارتجاف، تصلب العضلات و/أو ضعف، نعاس، ارتباك، مشاكل التنفس، صعوبة في الرضاعة. إذا أصيب طفلك بأي من هذه الأعراض، فقد تحتاج إلى الاتصال بطبيبك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />هناك خطر الشعور بالنعاس عند تناول أولانزابين. إذا حدث ذلك، لا تقم بالقيادة أو تشغيل أي أدوات أو آلات. أخبر طبيبك.</p><p dir="RTL"><strong>يحتوي برانزا على اللاكتوز</strong><br />يحتوي برانزا على اللاكتوز. يحتوي كل قرص مغطى بطبقة رقيقة من برانزا 5 ملغم و10 ملغم أقراص مغطاة بطبقة رقيقة على 89 ملغم أو 178 ملغم لاكتوز؛ على التوالي. إذا تم إخبارك من طبيبك أن لديك عدم تحمل لبعض السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما أخبرك طبيبك تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">سوف يخبرك طبيبك كم عدد الأقراص من برانزا يجب تناولها والمدة التي يجب الاستمرار في تناولها. تتراوح الجرعة اليومية من برانزا بين 5 ملغم و20 ملغم. استشر طبيبك إذا عادت إليك الأعراض مرة أخرى ولكن لا تتوقف عن تناول برانزا ما لم يقول لك الطبيب.</p><p dir="RTL">يجب أن تتناول أقراص برانزا مرة واحدة يومياً مع اتباع مشورة الطبيب. حاول تناول أقراصك في نفس الوقت كل يوم. لا يهم ما إذا كنت تتناولها مع أو بدون الطعام. أقراص برانزا معدة للاستخدام عن طريق الفم. يجب عليك بلع أقراص برانزا كاملة مع الماء.</p><p dir="RTL">لا يهدف الخط المحزز إلى كسر القرص.</p><p dir="RTL"><strong>إذا تناولت برانزا أكثر من اللازم</strong><br />المرضى الذين تناولوا أولانزابين أكثر من اللازم ظهرت عليهم الأعراض التالية: ضربات القلب السريعة ,اهتياج/عدوانية، مشاكل مع الكلام، حركات غير عادية (خاصة في الوجه أو اللسان) وانخفاض مستوى الوعي. أعراض أخرى قد تكون: الارتباك الحاد، نوبات (الصرع)، الغيبوبة، هو مزيج من الحمى، السرعة في التنفس، تعرق، تصلب العضلات والنعاس، تباطؤ في معدل التنفس، ارتفاع أو انخفاض ضغط الدم، إيقاعات غير طبيعية من القلب. اتصل بطبيبك أو المستشفى على الفور إذا كنت تواجه أي من الأعراض المذكورة أعلاه. اعرض على الطبيب عبوة الأقراص.</p><p dir="RTL"><strong>إذا نسيت تناول برانزا</strong><br />تناول الأقراص بمجرد أن تتذكر. لا تتناول جرعتين في يوم واحد.</p><p dir="RTL"><strong>إذا توقفت عن تناول برانزا</strong><br />لا تتوقف عن تناول أقراصك لمجرد أنك تشعر بتحسن. من المهم أن تستمر في تناول برانزا كما يخبرك طبيبك.</p><p dir="RTL">إذا توقفت فجأة عن تناول برانزا، قد تحدث بعض الأعراض مثل التعرق، عدم القدرة على النوم، رعشة، قلق أو غثيان وقيء. قد يقترح الطبيب انقاص الجرعة تدريجياً قبل وقف العلاج.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>أخبر طبيبك فوراً إذا كان لديك</strong><strong>:</strong></p><ul dir="rtl"><li>حركة غير عادية (من الآثار الجانبية الشائعة التي قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) غالباً في الوجه أو اللسان.</li><li>جلطات الدم في الأوردة (من الآثار الجانبية غير الشائعة التي قد تؤثر على ما يصل إلى 1 من كل 100 شخص) وخاصة في الساقين (تتضمن الأعراض تورم، ألم، واحمرار في الساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مما تسبب ألم في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض اطلب المشورة الطبية على الفور.</li><li>مزيج من الحمى، السرعة في التنفس، التعرق، تصلب العضلات و النعاس (لا يمكن تقدير تكرار هذا الأثر الجانبي من البيانات المتاحة).</li></ul><p dir="RTL">الآثار الجانبية الشائعة جداً (قد تحدث مع أكثر من 1 من كل 10 أشخاص) وتشمل زيادة الوزن؛ النعاس؛ وزيادة في مستويات البرولاكتين في الدم. في مراحل مبكرة من العلاج بعض المرضى قد يشعرون بالدوخة او بالدوار (مع نبض منخفض)، خاصة عند النهوض من وضعية الاستلقاء أو الجلوس. عادة تختفي هذه الأعراض من حالها ولكن إن لم تختفي يجب اخبار الطبيب بذلك.</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) وتشمل تغيرات في مستويات بعض خلايا الدم، الدهون التي تنتقل في الدم في بداية العلاج؛ زيادة مؤقتة في إنزيمات الكبد؛ الزيادة في مستوى السكر في الدم والبول؛ زيادة مستوى حمض اليوريا و فسفوكاينييز الكرياتنين في الدم؛ الشعور بالجوع أكثر؛ الدوخة؛ الأرق؛ الرعشة؛ حركات غير عادية (خلل الحركة)؛ الإمساك؛ جفاف الفم؛ طفح؛ فقدان القوة؛ التعب الشديد؛ احتباس الماء الذي يؤدي إلى تورم في اليدين، الكاحلين أو القدمين؛ الحمى؛ ألم المفاصل؛ الخلل الجنسي مثل انخفاض الرغبة الجنسية عند الذكور والإناث أو عدم القدرة على الانتصاب عند الذكور.</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تحدث في ما يصل إلى 1 من كل 100 شخص) وتشمل الحساسية (مثل، تورم في الفم والحلق، حكة، طفح)؛ سكري أو تفاقم مرض السكري، ويرتبط أحيانا مع الحماض الكيتونيّ &nbsp;(الكيتونات في الدم والبول) أو الغيبوبة؛ نوبات الصرع (عادة ترتبط بالمرضى الذين لديهم تاريخ مع النوبات (الصرع))؛ تشنج وتصلب في العضلات (تشمل حركات العین)؛ متلازمة&nbsp;الساق&nbsp;القلقة؛ مشاكل في الكلام؛ تأتأة؛ بطء معدل ضربات القلب؛ حساسية لأشعة الشمس؛ نزيف في الأنف، انتفاخ البطن؛ سيلان اللعاب؛ فقدان الذاكرة أو نسيان؛ سلس البول؛ نقص القدرة على التبول؛ تساقط الشعر؛ غياب أو انخفاض في فترات الحيض؛ والتغييرات في الثدي في الذكور والإناث مثل إنتاج حليب الثدي أو النمو غير الطبيعي.</p><p dir="RTL">الآثار الجانبية النادرة (قد تحدث في ما يصل إلى 1 من كل 1000 شخص) وتشمل خفض درجة حرارة الجسم الطبيعية؛ إيقاعات غير طبيعية للقلب؛ الموت المفاجئ غير المبرر؛ التهاب البنكرياس الذي يسبب آلام شديدة في المعدة، الحمى، أمراض الكبد وظهور اصفرار في الجلد وأجزاء بيضاء من العينين؛ مرض في العضلات ممثل في الأوجاع والآلام غير المبررة؛ والانتصاب لفترات طويلة و/أو مؤلمة.</p><p dir="RTL">آثار جانبية نادرة جداً تشمل ردود فعل تحسسية خطيرة مثل التفاعل الدوائي المترافق مع فرط الحمضات والأعراض الجهازية. يظهر التفاعل الدوائي المترافق مع فرط الحمضات والأعراض الجهازية بدايةً مثل أعراض الإنفلونزا مع طفح على الوجه ومن ثم طفح ممتد، ارتفاع درجة الحرارة، تضخم الغدد الليمفاوية، زيادة مستويات أنزيمات الكبد التي شوهدت في فحوصات الدم وزيادة في توع من خلايا الدم البيضاء (كثرة الحمضات).</p><p dir="RTL">خلال تناول أولانزابين، المرضى المسنين المصابين بالخرف قد يعانون من السكتة الدماغية، الالتهاب الرئوي، سلس البول، السقوط، التعب الشديد، الهلوسات البصرية، ارتفاع في درجة حرارة الجسم، احمرار في الجلد وصعوبة في المشي. تم الإبلاغ عن بعض الحالات الخطيرة والتي أدت إلى الوفاة خاصة في هذه المجموعة من المرضى.</p><p dir="RTL">أولانزابين قد يؤدي إلى تفاقم الأعراض في المرضى الذين يعانون من مرض باركنسون.</p><p dir="RTL">تشمل الآثار الجانبية غير المعروفة المشي أثناء النوم (والذي يتضمن الاستيقاظ والمشي أثناء النوم). &nbsp;</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة، أو في حال لاحظت ظهور أية آثار جانبية لم تذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية. &nbsp;</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أولانزابين.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من برانزا 5 ملغم أقراص مغطاة بطبقة رقيقة على 5 ملغم أولانزابين.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من برانزا 10 ملغم أقراص مغطاة بطبقة رقيقة على 10 ملغم أولانزابين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص:</em> لاكتوز، سيلليلوز بلوري مكروي، هيدروكسي بروبيل السلليلوز، كروسبوڤيدون وستيرات المغنيسيوم. <em>غلاف القرص:</em> أوبادري أبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">برانزا 5 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاء دائرية مغطاة بطبقة رقيقة منقوش عليها &ldquo;JI&rdquo; على أحد الجانبين و&quot;68&quot; على الجانب الآخر مع خط كسر في أشرطة من الألومنيوم/الألومنيوم.</p><p dir="RTL">برانزا 10 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاء دائرية مغطاة بطبقة رقيقة منقوش عليها &ldquo;JI&rdquo; على أحد الجانبين و&quot;69&quot; على الجانب الآخر مع خط كسر في أشرطة من الألومنيوم/الألومنيوم.</p><p dir="RTL">حجم العبوة: 30 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والشركة المصنعة</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2024/01؛ رقم النسخة SA3.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pranza 5 mg Film-coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 5 mg olanzapine.

Excipients with known effect: Lactose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

White round film-coated tablets embossed with “JI” on one side and “68” on the other side with a break line.

The score line is not intended for breaking the tablet. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong><br />Pranza is indicated for the treatment of schizophrenia.</p><p>Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.</p><p>Pranza is indicated for the treatment of moderate to severe manic episode.</p><p>In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong><br />Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day.</p><p>Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).</p><p>Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.</p><p>During treatment for schizophrenia, manic episode, and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.</p><p>Olanzapine can be given without regard for meals, as absorption is not affected by food. Gradual tapering of the dose should be considered when discontinuing olanzapine.</p><p>Pranza ODT orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. Removal of the intact orodispersible tablet from the mouth is difficult. Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister. Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk, or coffee) immediately before administration.</p><p>Olanzapine orodispersible tablet is bioequivalent to olanzapine film-coated tablets, with a similar rate and extent of absorption. It has the same dosage and frequency of administration as olanzapine film-coated tablets. Olanzapine orodispersible tablets may be used as an alternative to olanzapine film-coated tablets.</p><p><strong>Special populations</strong><br /><em>Elderly</em><br />A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).</p><p><em>Renal and/or hepatic impairment</em><br />A lower starting dose (5 mg) should be considered for such patients. In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh class A or B), the starting dose should be 5 mg and only increased with caution.</p><p><em>Smokers</em><br />The starting dose and dose range need not be routinely altered for non-smokers relative to smokers. The metabolism of olanzapine may be induced by smoking. Clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.5).</p><p>When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation, when indicated, should be conservative in such patients.</p><p>In cases where dose increments of 2.5 mg are considered necessary, Olanzapine coated tablets should be used.</p><p>(See sections 4.5 and 5.2.)</p><p><em>&nbsp;Paediatric population</em><br />Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy. A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short-term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2). &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 

Patients with known risk of narrow-angle glaucoma.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored during this period.</p><p><strong>Dementia-related psychosis and/or behavioural disturbances</strong><br />Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident. In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). The higher incidence of death was not associated with olanzapine dose (mean daily dose 4.4 mg) or duration of treatment. Risk factors that may predispose this patient population to increased mortality include age &gt; 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines. However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.</p><p>In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischaemic attack), including fatalities, were reported. There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors. Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment. The efficacy of olanzapine was not established in these trials.</p><p><strong>Parkinson&#39;s disease</strong><br />The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson&#39;s disease is not recommended. In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms. In these trials, patients were initially required to be stable on the lowest effective dose of anti-Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study. Olanzapine was started at 2.5 mg/day and titrated to a maximum of 15 mg/day based on investigator judgement.</p><p><strong>Neuroleptic Malignant Syndrome (NMS)</strong><br />NMS is a potentially life-threatening condition associated with antipsychotic medicinal products. Rare cases reported as NMS have also been received in association with olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine must be discontinued.</p><p><strong>Hyperglycaemia and diabetes</strong><br />Hyperglycaemia and/or development or exacerbation of diabetes, occasionally associated with ketoacidosis or coma, has been reported uncommonly, including some fatal cases (see section 4.8). In some cases, a prior increase in body weight has been reported, which may be a predisposing factor. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g., measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter. Patients treated with any antipsychotic medicines, be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. Weight should be monitored regularly, e.g., at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter.</p><p><strong>Lipid alterations</strong><br />Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials (see section 4.8). Lipid alterations should be managed as clinically appropriate, particularly in dyslipidemic patients and in patients with risk factors for the development of lipids disorders. Patients treated with any antipsychotic medicines, including olanzapine film-coated tablets/olanzapine orodispersible tablets, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g., at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.</p><p><strong>Anticholinergic activity</strong><br />While olanzapine demonstrated anticholinergic activity&nbsp;<em>in vitro</em>, experience during the clinical trials revealed a low incidence of related events. However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.</p><p><strong>Hepatic function</strong><br />Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines. In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.</p><p><strong>Neutropenia</strong><br />Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).</p><p><strong>Discontinuation of treatment</strong><br />Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (&ge; 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.</p><p><strong>QT interval</strong><br />In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] &ge; 500 milliseconds [msec] at any time post-baseline in patients with baseline QTcF &lt; 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.</p><p><strong>Thromboembolism</strong><br />Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (&ge; 0.1% and &lt; 1%). A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established. However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism, all possible risk factors of VTE e.g., immobilisation of patients, should be identified and preventive measures undertaken.</p><p><strong>General CNS activity</strong><br />Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol. As it exhibits&nbsp;<em>in vitro</em>&nbsp;dopamine antagonism, olanzapine may antagonise the effects of direct and indirect dopamine agonists.</p><p><strong>Seizures</strong><br />Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold. Seizures have been reported to occur uncommonly in patients when treated with olanzapine. In most of these cases, a history of seizures or risk factors for seizures were reported.</p><p><strong>Tardive dyskinesia</strong><br />In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment-emergent dyskinesia. However, the risk of tardive dyskinesia increases with long-term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or even arise after discontinuation of treatment.</p><p><strong>Postural hypotension</strong><br />Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials. It is recommended that blood pressure is measured periodically in patients over 65 years.</p><p><strong>Sudden cardiac death</strong><br />In postmarketing reports with olanzapine, the event of sudden cardiac death has been reported in patients with olanzapine. In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics. In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.</p><p><strong>Paediatric population</strong><br />Olanzapine is not indicated for use in the treatment of children and adolescents. Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels (see sections 4.8 and 5.1).</p><p><strong>Pranza contains lactose</strong><br />Pranza contains lactose. Each film-coated tablet contains 89 mg lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><strong>Potential interactions affecting olanzapine</strong><br />Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.</p><p><strong>Induction of CYP1A2</strong><br />The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations. Only slight to moderate increase in olanzapine clearance has been observed. The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).</p><p><strong>Inhibition of CYP1A2</strong><br />Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine C<sub>max</sub>&nbsp;following fluvoxamine was 54% in female non-smokers and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108%, respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.</p><p><strong>Decreased bioavailability</strong><br />Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.</p><p>Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.</p><p><strong>Potential for olanzapine to affect other medicinal products</strong><br />Olanzapine may antagonise the effects of direct and indirect dopamine agonists.</p><p>Olanzapine does not inhibit the main CYP450 isoenzymes&nbsp;<em>in vitro</em>&nbsp;(e.g., 1A2, 2D6, 2C9, 2C19, 3A4). Thus, no particular interaction is expected, as verified through&nbsp;<em>in vivo</em>&nbsp;studies, where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2), or diazepam (CYP3A4 and 2C19).</p><p>Olanzapine showed no interaction when co-administered with lithium or biperiden.</p><p>Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.</p><p><strong>General CNS activity</strong><br />Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.</p><p>The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson&#39;s disease and dementia is not recommended (see section 4.4).</p><p><strong>QTc interval</strong><br />Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />There are no adequate and well-controlled studies in pregnant women. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine. Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>New born infants exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p><strong>Breast-feeding</strong><br />In a study in breast-feeding, healthy women, olanzapine was excreted in breast milk. Mean infant exposure (mg/kg) at steady-state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg). Patients should be advised not to breast-feed an infant if they are taking olanzapine.</p><p><strong>Fertility</strong><br />Effects on fertility are unknown (see section 5.3 for preclinical information).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br /><u>Adults</u><br />The most frequently (seen in &ge; 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.</p><p><strong>Tabulated list of adverse reactions</strong><br />The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the data available).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilia</p><p>Leukopenia<sup>10</sup></p><p>Neutropenia<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weight gain<sup>1</sup></p></td><td style="vertical-align:top"><p>Elevated cholesterol levels<sup>2,3</sup></p><p>Elevated glucose levels<sup>4</sup></p><p>Elevated triglyceride levels<sup>2,5</sup></p><p>Glucosuria</p><p>Increased appetite</p></td><td style="vertical-align:top"><p>Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4)<sup>&nbsp;11</sup></p></td><td style="vertical-align:top"><p>Hypothermia<sup>12</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Akathisia<sup>6</sup></p><p>Parkinsonism<sup>6</sup></p><p>Dyskinesia<sup>6</sup></p></td><td style="vertical-align:top"><p>Seizures where in most cases a history of seizures or risk factors for seizures were reported&nbsp;<sup>11</sup></p><p>Dystonia (including oculogyration)<sup>&nbsp;11</sup></p><p>Tardive dyskinesia<sup>11</sup></p><p>Amnesia&nbsp;<sup>9</sup></p><p>Dysarthria</p><p>Stuttering<sup>11</sup></p><p>Restless Legs Syndrome<sup>11</sup></p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome (see section 4.4)&nbsp;<sup>12</sup></p><p>Discontinuation symptoms<sup>7, 12</sup></p></td><td style="vertical-align:top"><p>Somnambulism</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bradycardia</p><p>QTc prolongation (see section 4.4)</p></td><td style="vertical-align:top"><p>Ventricular tachycardia/ fibrillation, sudden death (see section 4.4)<sup>&nbsp;11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Epistaxis<sup>9</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mild, transient anticholinergic effects including constipation and dry mouth</p></td><td style="vertical-align:top"><p>Abdominal distension<sup>9</sup></p><p>Salivary hypersecretion<sup>11</sup></p></td><td style="vertical-align:top"><p>Pancreatitis<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatitis (including hepatocellular, cholestatic or mixed liver injury)<sup>&nbsp;11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Photosensitivity reaction</p><p>Alopecia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia<sup>9</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary incontinence, urinary retention</p><p>Urinary hesitation<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Erectile dysfunction in males</p><p>Decreased libido in males and females</p></td><td style="vertical-align:top"><p>Amenorrhea</p><p>Breast enlargement</p><p>Galactorrhea in females</p><p>Gynaecomastia/breast enlargement in males</p></td><td style="vertical-align:top"><p>Priapism<sup>12</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia</p><p>Fatigue</p><p>Oedema</p><p>Pyrexia<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Elevated plasma prolactin levels<sup>8</sup></p></td><td style="vertical-align:top"><p>Increased alkaline phosphatase<sup>10</sup></p><p>High creatine phosphokinase<sup>11</sup></p><p>High Gamma Glutamyltransferase<sup>10</sup></p><p>High uric acid&nbsp;<sup>10</sup></p></td><td style="vertical-align:top"><p>Increased total bilirubin</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>1</sup>Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Following short-term treatment (median duration 47 days), weight gain &ge; 7% of baseline body weight was very common (22.2%); &ge; 15% was common (4.2%); and &ge; 25% was uncommon (0.8%). Patients gaining &ge; 7%, &ge; 15% and &ge; 25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively).</p><p><sup>&nbsp;2</sup>Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.</p><p><sup>&nbsp;3</sup>Observed for fasting normal levels at baseline (&lt; 5.17 mmol/l) which increased to high (&ge; 6.2 mmol/l). Changes in total fasting cholesterol levels from borderline at baseline (&ge; 5.17 - &lt; 6.2 mmol/l) to high (&ge; 6.2 mmol/l) were very common.</p><p><sup>&nbsp;4</sup>Observed for fasting normal levels at baseline (&lt; 5.56 mmol/l) which increased to high (&ge; 7 mmol/l). Changes in fasting glucose from borderline at baseline (&ge; 5.56 - &lt; 7 mmol/l) to high (&ge; 7 mmol/l) were very common.</p><p><sup>&nbsp;5</sup>Observed for fasting normal levels at baseline (&lt; 1.69 mmol/l) which increased to high (&ge; 2.26 mmol/l). Changes in fasting triglycerides from borderline at baseline (&ge; 1.69 mmol/l - &lt; 2.26 mmol/l) to high (&ge; 2.26 mmol/l) were very common.</p><p><sup>&nbsp;6</sup>In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo. Olanzapine-treated patients had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol. In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes.</p><p><sup>&nbsp;7</sup>Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.</p><p><sup>&nbsp;8</sup>&nbsp;In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine-treated patients with normal baseline prolactin value. In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range.</p><p><sup>&nbsp;9</sup>&nbsp;Adverse event identified from clinical trials in the Olanzapine Integrated Database.</p><p><sup>&nbsp;10</sup>&nbsp;As assessed by measured values from clinical trials in the Olanzapine Integrated Database.</p><p><sup>&nbsp;11</sup>&nbsp;Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database.</p><p><sup>&nbsp;12</sup>&nbsp;Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.</p><p><strong>&nbsp;Long-term exposure (at least 48 weeks)</strong><br />The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.</p><p><strong>Additional information on special populations</strong><br />In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4). Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls. Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.</p><p>In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson&#39;s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.</p><p>In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels (&ge;10%) of tremor, dry mouth, increased appetite, and weight gain. Speech disorder was also reported commonly. During treatment with olanzapine in combination with lithium or divalproex, an increase of &ge; 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks). Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of &ge;7% from baseline body weight in 39.9% of patients.</p><p><u>Paediatric population</u><br />Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years. Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.</p><p>The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients. Clinically significant weight gain (&ge; 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Very common:</em>&nbsp;Weight gain<sup>13</sup>, elevated triglyceride levels<sup>14</sup>, increased appetite.</p><p><em>Common:</em>&nbsp;Elevated cholesterol levels<sup>15</sup>.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p><em>Very common:</em>&nbsp;Sedation (including: hypersomnia, lethargy, somnolence).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Common:</em>&nbsp;Dry mouth.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p><p><em>Very common:</em>&nbsp;Elevations of hepatic aminotransferases (ALT/AST; see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p><em>Very common:</em>&nbsp;Decreased total bilirubin, increased GGT, elevated plasma prolactin levels<sup>16</sup>.</p></td></tr></tbody></table><p><sup>13</sup>Following short-term treatment (median duration 22 days), weight gain &ge; 7% of baseline body weight (kg) was very common (40.6%); &ge; 15% of baseline body weight was common (7.1%) and &ge; 25% was common (2.5%). With long-term exposure (at least 24 weeks), 89.4% gained &ge; 7%, 55.3% gained &ge; 15% and 29.1% gained &ge; 25% of their baseline body weight.</p><p><sup>14</sup>Observed for fasting normal levels at baseline (&lt; 1.016 mmol/l) which increased to high (&ge; 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (&ge; 1.016 mmol/l - &lt; 1.467 mmol/l) to high (&ge; 1.467 mmol/l).</p><p><sup>15</sup>Changes in total fasting cholesterol levels from normal at baseline (&lt; 4.39 mmol/l) to high (&ge; 5.17 mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at baseline (&ge; 4.39 - &lt; 5.17 mmol/l) to high (&ge; 5.17 mmol/l) were very common.</p><p><sup>16</sup>Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Signs and symptoms</strong><br />Very common symptoms in overdose (&gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.</p><p>Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (&lt;2% of overdose cases), and cardiopulmonary arrest. Fatal outcomes have been reported for acute overdoses as low as 450 mg, but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine.</p><p><strong>Management</strong><br />There is no specific antidote for olanzapine. Induction of emesis is not recommended. Standard procedures for management of overdose may be indicated (i.e., gastric lavage, administration of activated charcoal). The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.</p><p>Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function. Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity, since beta stimulation may worsen hypotension. Cardiovascular monitoring is necessary to detect possible arrhythmias. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines, ATC code N05A H03.</p><p><strong>Pharmacodynamic effects</strong><br />Olanzapine is an antipsychotic, antimanic, and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.</p><p>In preclinical studies, olanzapine exhibited a range of receptor affinities (K<sub>i</sub>&nbsp;&lt;100nM) for serotonin 5HT<sub>2A/2C</sub>, 5HT<sub>3</sub>, 5HT<sub>6</sub>; dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, D<sub>5</sub>; cholinergic muscarinic receptors M<sub>1</sub>-M<sub>5</sub>; &alpha;<sub>1</sub>&nbsp;adrenergic; and histamine H<sub>1</sub>&nbsp;receptors. Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile. Olanzapine demonstrated a greater&nbsp;<em>in vitro</em>&nbsp;affinity for serotonin 5HT<sub>2</sub>&nbsp;than dopamine D<sub>2</sub>&nbsp;receptors and greater 5HT<sub>2</sub>&nbsp;than D<sub>2</sub>&nbsp;activity in&nbsp;<em>in vivo</em>&nbsp;models. Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function. Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects. Unlike some other antipsychotic agents, olanzapine increases responding in an &#39;anxiolytic&#39; test.</p><p>In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT<sub>2A</sub>&nbsp;than dopamine D<sub>2</sub>&nbsp;receptor occupancy. In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D<sub>2</sub>&nbsp;occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.</p><p><strong>Clinical efficacy</strong><br />In two of two placebo- and two of three comparator-controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.</p><p>In a multinational, double-blind, comparative study of schizophrenia, schizoaffective and related disorders, which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (<em>P</em>&nbsp;= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).</p><p>In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks. Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks. In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.</p><p>In a 12 month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence. Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.</p><p>In a second 12 month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%;&nbsp;<em>P</em>&nbsp;= 0.055).</p><p>In an 18 month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.</p><p><strong>Paediatric population</strong><br />Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term studies in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents. Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/day. During treatment with olanzapine, adolescents gained significantly more weight compared with adults. The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults. There are no controlled data on maintenance of effect or long term safety (see sections 4.4 and 4.8)<em>.</em>&nbsp;Information on long term safety is primarily limited to open-label, uncontrolled data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olanzapine orodispersible tablet is bioequivalent to olanzapine film-coated tablet, with a similar rate and extent of absorption. Olanzapine orodispersible tablets may be used as an alternative to olanzapine film-coated tablets.</p><p><strong>Absorption</strong><br />Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Absolute oral bioavailability relative to intravenous administration has not been determined.</p><p><strong>Distribution</strong><br />The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ml. Olanzapine is bound predominantly to albumin and &alpha;<sub>1</sub>-acid-glycoprotein.</p><p><strong>Biotransformation</strong><br />Olanzapine is metabolised in the liver by conjugative and oxidative pathways. The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier. Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites; both exhibited significantly less&nbsp;<em>in vivo</em>&nbsp;pharmacological activity than olanzapine in animal studies. The predominant pharmacologic activity is from the parent, olanzapine.</p><p><strong>Elimination</strong><br />After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.</p><p>In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hours) and the clearance was reduced (17.5 versus 18.2 l/hr). The pharmacokinetic variability observed in the elderly is within the range for the non-elderly. In 44 patients with schizophrenia &gt;65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.</p><p>In female versus male subjects, the mean elimination half-life was somewhat prolonged (36.7 versus 32.3 hours) and the clearance was reduced (18.9 versus 27.3 l/hr). However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n = 467) as in male patients (n = 869).</p><p><u>Renal impairment</u><br />In renally impaired patients (creatinine clearance &lt;10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hours) or clearance (21.2 versus 25.0 l/hr). A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites.</p><p><u>Hepatic impairment</u><br />A small study of the effect of impaired liver function in 6 subjects with clinically significant (Childs Pugh Classification A (n = 5) and B (n = 1)) cirrhosis revealed little effect on the pharmacokinetics of orally administered olanzapine (2.5 &ndash; 7.5 mg single dose): Subjects with mild to moderate hepatic dysfunction had slightly increased systemic clearance and faster elimination half-time compared to subjects with no hepatic dysfunction (n = 3). There were more smokers among subjects with cirrhosis (4/6; 67 %) than among subjects with no hepatic dysfunction (0/3; 0 %).</p><p><u>Smoking</u><br />In non-smoking versus smoking subjects (males and females), the mean elimination half-life was prolonged (38.6 versus 30.4 hours) and the clearance was reduced (18.6 versus 27.7 l/hr).</p><p>The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers. However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.</p><p>In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.</p><p><u>Paediatric population</u><br />Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults. In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents. Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers. Such factors possibly contribute to the higher average exposure observed in adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute (single-dose) toxicity</strong><br />Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain. The median lethal doses were approximately 210 mg/kg (mice) and 175 mg/kg (rats). Dogs tolerated single oral doses up to 100 mg/kg without mortality. Clinical signs included sedation, ataxia, tremors, increased heart rate, laboured respiration, miosis, and anorexia. In monkeys, single oral doses up to 100 mg/kg resulted in prostration and, at higher doses, semi-consciousness.</p><p><strong>Repeated-dose toxicity</strong><br />In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders. Tolerance developed to the CNS depression. Growth parameters were decreased at high doses. Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland.</p><p><strong>Haematologic toxicity</strong><br />Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found. Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12 mg dose). In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.</p><p><strong>Reproductive toxicity</strong><br />Olanzapine had no teratogenic effects. Sedation affected mating performance of male rats. Oestrous cycles were affected at doses of 1.1 mg/kg (3-times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/kg (9-times the maximum human dose). In the offspring of rats given olanzapine, delays in foetal development and transient decreases in offspring activity levels were seen.</p><p><strong>Mutagenicity</strong><br />Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;mammalian tests.</p><p><strong>Carcinogenicity</strong><br />Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core:</em><br />-&nbsp; &nbsp;Lactose<br />-&nbsp;&nbsp;&nbsp;Microcrystalline cellulose<br />-&nbsp;&nbsp;&nbsp;Hydroxypropyl cellulose<br />-&nbsp; &nbsp;Crospovidone<br />-&nbsp;&nbsp;&nbsp;Magnesium stearate</p><p><em>Tablet coat:</em><br />-&nbsp;&nbsp;&nbsp;Opadry white</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p><p>Pack size: 30 Film-coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical industries
Al-Kharj Road
P.O.BOX 106229
Riyadh 11666, Saudi Arabia 
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12 October 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>